A Phase 1, Single-center, Open-label, Randomized, Parallel Group, Single-dose Study to Compare the Pharmacokinetics of Subcutaneous Itepekimab Administered With an Autoinjector Versus Prefilled Syringe in Healthy Participants
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Itepekimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Sanofi
Most Recent Events
- 07 Nov 2023 New trial record